Literature DB >> 12473596

Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma.

Shuho Semba1, Nanami Itoh, Masafumi Ito, Emile M Youssef, Masaru Harada, Toshiyuki Moriya, Wataru Kimura, Mitsunori Yamakawa.   

Abstract

PURPOSE: Premature death associated with colorectal adenocarcinoma occurs in PIK3CG(-/-) mice and overexpression of PIK3CG in colon cancer cells suppresses cell proliferation. We examined expression levels of PIK3CG, a catalytic subunit of phosphatidylinositide 3-OH kinase (PI3K), in colon cancer cells to investigate the hypothesis that PIK3CG might contribute to the growth and progression of colorectal cancers. EXPERIMENTAL
DESIGN: The effects of LY294002, a PI3K inhibitor, on cell growth were examined to elucidate the role of the PI3K-Akt/protein kinase B (PKB) pathway in colon cancer. We used reverse transcription-PCR, Western blotting, and immunohistochemical analyses to examine PIK3CG mRNA and protein expression levels in colon cancer cells and primary colorectal cancers. To clarify the mechanism responsible for the silencing of this gene in colon cancers, we performed methylation-sensitive PCR analysis of DNA digested with HpaII and MspI and analyzed PI3KCG expression in DLD-1 and LoVo cells treated with the demethylating agent 5-aza-2'-deoxycytidine (5-Aza).
RESULTS: LY294002 suppressed growth and decreased expression of Akt (Ser(473)) expression in cancer cells. Three (60%) of 5 colon cancer cell lines did not express PIK3CG, but hypermethylation at CpG sites of the promoter regions of this gene was detected. However, 5-Aza-treated DLD-1 and LoVo cells did express PIK3CG. Reduction of PIK3CG expression was detected immunohistochemically in 85% of human colorectal cancers and was closely associated with invasion, metastasis, and poor differentiation. Down-regulation of PIK3CG expression and hypermethylation of promoter regions were also detected in primary colon cancers.
CONCLUSIONS: Our findings suggest that the silencing of the PIK3CG gene plays an important role in inhibiting the PI3K-Akt/PKB signaling system responsible for tumorigenesis and the progression of colorectal cancers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473596

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  24 in total

1.  Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation.

Authors:  Yutaka Kondo; Lanlan Shen; Pearlly S Yan; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

2.  Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines.

Authors:  Xiaoli Shen; Ramanjaneya V R Mula; B Mark Evers; Miriam Falzon
Journal:  Regul Pept       Date:  2007-01-10

3.  PIK3C2G copy number is associated with clinical outcomes of colorectal cancer patients treated with oxaliplatin.

Authors:  Ajian Li; Hui Chen; Moubin Lin; Chenbo Zhang; Erjiang Tang; Jian Peng; Qing Wei; Huaguang Li; Lu Yin
Journal:  Int J Clin Exp Med       Date:  2015-01-15

4.  Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.

Authors:  Piotr G Rychahou; Lindsey N Jackson; Scott R Silva; Srinivasan Rajaraman; B Mark Evers
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

5.  Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).

Authors:  Hannah Carter; Josue Samayoa; Ralph H Hruban; Rachel Karchin
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

6.  High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.

Authors:  U A Miskad; S Semba; H Kato; Y Matsukawa; Y Kodama; E Mizuuchi; N Maeda; K Yanagihara; H Yokozaki
Journal:  Virchows Arch       Date:  2007-01-18       Impact factor: 4.064

7.  Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Authors:  Muling Mao; Feng Tian; John M Mariadason; Chun C Tsao; Robert Lemos; Farshid Dayyani; Y N Vashisht Gopal; Zhi-Qin Jiang; Ignacio I Wistuba; Xi M Tang; William G Bornman; Gideon Bollag; Gordon B Mills; Garth Powis; Jayesh Desai; Gary E Gallick; Michael A Davies; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

8.  Epigenetic contributions to cancer metastasis.

Authors:  David I Rodenhiser
Journal:  Clin Exp Metastasis       Date:  2008-04-02       Impact factor: 5.150

9.  PTHrP increases xenograft growth and promotes integrin alpha6beta4 expression and Akt activation in colon cancer.

Authors:  Xiaoli Shen; Piotr G Rychahou; B Mark Evers; Miriam Falzon
Journal:  Cancer Lett       Date:  2007-10-26       Impact factor: 8.679

Review 10.  Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways.

Authors:  Qiang Shen; Powel H Brown
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-01       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.